Unlike markets that can sustain 'me-too' drugs, South Korean biotechs strategically focus on high-risk areas like novel biology and diverse modalities. This high 'innovation quotient' is their necessary and deliberate path to global competitiveness, embracing target and modality risk as a core strategy.
While speed is crucial in clinical trials, the ability to transfer data across borders is a growing pain point. Data privacy regulations, particularly in China, complicate due diligence and global collaboration, making data portability a key factor for efficiency and a significant hurdle for M&A.
A key mindset difference exists between Asian and Western healthcare investors. Asian VCs are often generalists who prefer de-risked, later-stage assets and even invest in infrastructure like hospitals. This indicates a more risk-averse thesis compared to specialized Western VCs focused on early-stage biotech.
Global pharma companies must be flexible when structuring deals with Chinese biotechs. Many Chinese firms face post-IPO obligations requiring them to retain Greater China rights and be the Marketing Authorization Holder to book revenue, which prevents simple global licensing deals.
For Korean biotechs, 'thinking globally' often starts regionally. A significant portion of their deals are with other Asian companies. This strategy allows them to combine technologies and create value, using partnerships in markets like Japan as a crucial step before approaching Western markets.
South Korea's biotech sector is poised for a 'J-curve' of rapid growth. However, realizing this potential depends on overcoming two critical hurdles: accessing sufficient capital to fund development through key value inflection points and building local expertise in global clinical strategy.